MedTech Terms
    The authoritative reference
    All terms

    Counterfeit Parts and Suspect Components

    Risk of unauthorized, fraudulent, or substandard components entering the supply chain.

    Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 5, 2026

    Definition

    Counterfeit electronic components and substandard materials have caused field failures and recalls in MedTech. Mitigation includes authorized-distributor sourcing, incoming inspection, and AS6081/AS6171-style detection methods for electronics.
    What the regulation says
    Regulators emphasize the critical importance of preventing counterfeit parts and suspect components from entering the MedTech supply chain, as highlighted by FDA guidance on supply chain integrity and the requirements of ISO 13485:2016 for purchasing control (clause 7.4). The EU MDR (Regulation (EU) 2017/745) also requires manufacturers to implement robust quality management systems that address supply chain risks, including those related to component authenticity, as outlined in Annex I, Chapter I, General Requirements, Point 2.

    What this means in practice

    Heightened concern after EUA-era ventilator and respirator supply chains exposed widespread component fraud.

    Examples

    • A medical device manufacturer implements a new supplier qualification process requiring all component suppliers to provide certificates of authenticity and traceability documentation for critical components.
    • During incoming inspection, a MedTech company uses X-ray fluorescence (XRF) spectroscopy to verify the material composition of received components against specifications, identifying a batch of resistors made with incorrect alloys.
    • Following a field failure report, an investigation reveals that a crucial integrated circuit in an implanted device was a remarked, substandard component obtained from an unauthorized broker, leading to a product recall.
    Common pitfalls
    • •A common pitfall is relying solely on price as a purchasing criterion, which can inadvertently lead to the acquisition of counterfeit or substandard components.
    • •Another mistake is neglecting to conduct regular audits of suppliers and their quality systems, missing early indicators of potential supply chain vulnerabilities.
    • •Failing to implement a robust incoming inspection process risks integrating non-conforming components directly into medical devices, jeopardizing patient safety and device effectiveness.
    • •Misinterpreting “authorized distributor” as a blanket guarantee of authenticity without verifying the distributor’s specific authorization for the purchased components is a common misconception.
    • •Overlooking the need for specialized training for personnel involved in component procurement and inspection can lead to inadequate identification of suspect parts.

    Frequently asked questions

    The primary risk is the potential for device malfunction, patient harm, and compromise of device safety and effectiveness, leading to recalls and significant regulatory non-compliance issues.
    Grouped by theme

    Primary references

    3 sources
    Link health: 3 verified· last checked 2026-06-20
    SAE·1FDA·1ISO·1
    1. 1
      SAE AS6081
      Verified
      SAEsae.org
    2. 2
      FDA - Device Manufacturing
      Verified
      FDAfda.gov
    3. 3
      ISO 13485 Standard Page
      Verified
      ISOiso.org

    Inline markers like [1] jump to the matching reference above.